A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer

Inclusion Criteria:

- Have histological or cytological evidence of a diagnosis of cancer that is advanced
and/or metastatic for which available standard therapies have failed to provide
clinical benefit for their disease

- For Dose Escalation (Part A): cancer, either a solid tumor or a lymphoma

- For Dose Confirmation (Part B): cancer, either a solid tumor or a lymphoma

- Have the presence of measureable or non-measureable disease (Part A) or measureable
disease (Part B) as defined by the Response Evaluation Criteria in Solid Tumors or
the Revised Response Criteria for Malignant Lymphoma

- Have adequate hematologic, hepatic and renal function

- Have a performance status less than or equal to 2 on the Eastern Cooperative Oncology
Group scale

- Have discontinued all previous therapies for cancer (including chemotherapy,
radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents or
14 days for nonmyelosuppressive agents

- Have an estimated life expectancy of greater than or equal to 12 weeks

- Are able to swallow capsules

Exclusion Criteria:

- Have an echocardiogram with clinically significant abnormalities

- For Dose Escalation (Part A): Have central nervous system malignancy or metastasis

- For Dose Confirmation (Part B): Have symptomatic central nervous system malignancy
or metastasis

- Have an acute leukemia

- Have a history of any other cancer (except non-melanoma skin cancer or carcinoma
in-situ of the cervix), unless in complete remission and stopped all therapy for that
disease for a minimum of 3 years

- Have received an autologous or allogeneic stem-cell transplant within 75 days of the
initial dose of study drug